Top 0.01% — Titan
Brian Druker
Oncology · Hematologic Oncology
Portland, United States
140 H-Index
30,777 Citations
2,138 Total Impact
GLLasker-DeBakey Clinical Medical Research Award (2009)0
GLJapan Prize (2012)0
GLAlbany Medical Center Prize0
Overview
Brian Druker is an oncology specialist with an H-index of 140 at Oregon Health & Science University. Developed imatinib (Gleevec), the first targeted cancer therapy for CML. Based in Portland, United States.
For Patients
- Pioneered the Targeted BCR-ABL tyrosine kinase inhibition for CML, a technique still used by doctors worldwide
- Research is cited 31K+ times by other doctors and scientists, indicating significant influence on medical research
- Currently at Oregon Health & Science University in Portland, United States
Biography
Brian Druker is an American oncologist who developed imatinib (Gleevec), the first successful targeted cancer therapy, transforming chronic myeloid leukemia from a fatal disease into a manageable condition. He is director of the Knight Cancer Institute at Oregon Health & Science University.
Affiliations & Institutions
Research Impact
10 Publications
30,777 Total Citations
10K+ Citation Milestone
Publication Timeline
Published In
New England Journal of MedicineNature MedicineJournal of Clinical OncologyNature
Key Publications
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Areas of Expertise
Pioneering Techniques
Medical Specialties
Clinical Knowledge & Procedures
Legacy Timeline
The life and contributions of Brian Druker
1993
Began clinical trials of STI571 (imatinib)
Initiated first human trials of the BCR-ABL tyrosine kinase inhibitor
2001
FDA approved imatinib (Gleevec) for CML
Gleevec received accelerated FDA approval, transforming CML treatment
2009
Lasker Award
Received the Lasker-DeBakey Clinical Medical Research Award for targeted cancer therapy
2012
Japan Prize
Awarded the Japan Prize for groundbreaking cancer research
Media Archive